观察|国产自身免疫创新药进入收获期,千亿赛道如何突围?

澎湃新闻
18 Feb

“公司2016年成立的时候,是肿瘤免疫治疗最热的时候,当时投资人希望我们做肿瘤免疫治疗,但我们想找到更符合时代发展趋势的药物领域,坚持先做自身免疫性疾病。”近日,康诺亚(2162.HK)董事会主席、执行董事兼首席执行官陈博在接受澎湃新闻记者采访时提到了这件往事。  时间过去近十年,令陈博和不少业内人士感到高兴的是,国产自身免疫治疗药物越来越受到关注,并已加速崛起。2024年就有多款国产自身免疫治疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10